Enhanced malaria msp-1 subunit vaccine
AssigneesHawaii Biotect Inc., University of Hawaii
InventorsDavid E. Clements, Kae Myriam Pusic, George N.S. Hui
Life of this patent
Estimating the term…
Loading patent…
AssigneesHawaii Biotect Inc., University of Hawaii
InventorsDavid E. Clements, Kae Myriam Pusic, George N.S. Hui
Estimating the term…
Recombinant subunit proteins derived from the MSP-1 C-terminal region of the parasite Plasmodium falciparum are described that have enhanced immunogenic properties. Selected regions of p33 have been combined with p19 to enhance the immunogenic potential of the p19 core region. As the constructs represent discontinuous segments fused to create unique proteins, the recombinant proteins expressed are not found in nature. The enhanced immunogenic potential of the disclosed recombinant proteins provided for strong, consistent and specific antibody responses. The disclosed recombinant subunit proteins are vaccine candidates for protection against infection with malaria.
MSP-1 C-terminal recombinant subunit proteins with enhanced immunogenic properties comprising:
Vaccine formulations comprising MSP-1 C-terminal subunit proteins capable of eliciting protection from malaria infection.
Dependencies are inferred from the claim text.